Melanoma vaccines as a therapeutic option

J. Michael McGee, Joseph A. Price, Jary S. Mayes, Marion R. Patten, Karen F. Malnar

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background. In 1998, 41,600 new cases of melanoma with 7,300 deaths were expected. Worldwide, the incidence has risen 5% a year against a backdrop of generally decreasing cancer trends. Later stages of melanoma carry a severe prognosis. The need for newer, more effective therapeutic strategies for cancer is obvious. For melanoma, early diagnosis and surgical treatment are the only options that are currently curative. Chemotherapy and radiation therapy are of limited efficacy. Methods. We reviewed the various forms of immunotherapy, concentrating on vaccine therapy. We then reviewed the history of our own vaccine in the context of the field of immunotherapy, and compared efficacy, immune response, production methods, and survival. Results. Survival is improved among recipients of melanoma vaccine when compared with patients receiving conventional therapy. Conclusions. Immunotherapy in the form of melanoma vaccines is better than conventional therapy and is trending toward purer antigenic preparations.

Original languageEnglish
Pages (from-to)698-704
Number of pages7
JournalSouthern Medical Journal
Volume92
Issue number7
DOIs
StatePublished - 1 Jul 1999

Fingerprint

Melanoma
Vaccines
Immunotherapy
Therapeutics
Active Immunotherapy
Survival
Early Diagnosis
Neoplasms
Radiotherapy
History
Drug Therapy
Incidence

Cite this

McGee, J. M., Price, J. A., Mayes, J. S., Patten, M. R., & Malnar, K. F. (1999). Melanoma vaccines as a therapeutic option. Southern Medical Journal, 92(7), 698-704. https://doi.org/10.1097/00007611-199907000-00008
McGee, J. Michael ; Price, Joseph A. ; Mayes, Jary S. ; Patten, Marion R. ; Malnar, Karen F. / Melanoma vaccines as a therapeutic option. In: Southern Medical Journal. 1999 ; Vol. 92, No. 7. pp. 698-704.
@article{f0265434fc4947de95a7c0e827341dae,
title = "Melanoma vaccines as a therapeutic option",
abstract = "Background. In 1998, 41,600 new cases of melanoma with 7,300 deaths were expected. Worldwide, the incidence has risen 5{\%} a year against a backdrop of generally decreasing cancer trends. Later stages of melanoma carry a severe prognosis. The need for newer, more effective therapeutic strategies for cancer is obvious. For melanoma, early diagnosis and surgical treatment are the only options that are currently curative. Chemotherapy and radiation therapy are of limited efficacy. Methods. We reviewed the various forms of immunotherapy, concentrating on vaccine therapy. We then reviewed the history of our own vaccine in the context of the field of immunotherapy, and compared efficacy, immune response, production methods, and survival. Results. Survival is improved among recipients of melanoma vaccine when compared with patients receiving conventional therapy. Conclusions. Immunotherapy in the form of melanoma vaccines is better than conventional therapy and is trending toward purer antigenic preparations.",
author = "McGee, {J. Michael} and Price, {Joseph A.} and Mayes, {Jary S.} and Patten, {Marion R.} and Malnar, {Karen F.}",
year = "1999",
month = "7",
day = "1",
doi = "10.1097/00007611-199907000-00008",
language = "English",
volume = "92",
pages = "698--704",
journal = "Southern Medical Journal",
issn = "0038-4348",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "7",

}

McGee, JM, Price, JA, Mayes, JS, Patten, MR & Malnar, KF 1999, 'Melanoma vaccines as a therapeutic option', Southern Medical Journal, vol. 92, no. 7, pp. 698-704. https://doi.org/10.1097/00007611-199907000-00008

Melanoma vaccines as a therapeutic option. / McGee, J. Michael; Price, Joseph A.; Mayes, Jary S.; Patten, Marion R.; Malnar, Karen F.

In: Southern Medical Journal, Vol. 92, No. 7, 01.07.1999, p. 698-704.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Melanoma vaccines as a therapeutic option

AU - McGee, J. Michael

AU - Price, Joseph A.

AU - Mayes, Jary S.

AU - Patten, Marion R.

AU - Malnar, Karen F.

PY - 1999/7/1

Y1 - 1999/7/1

N2 - Background. In 1998, 41,600 new cases of melanoma with 7,300 deaths were expected. Worldwide, the incidence has risen 5% a year against a backdrop of generally decreasing cancer trends. Later stages of melanoma carry a severe prognosis. The need for newer, more effective therapeutic strategies for cancer is obvious. For melanoma, early diagnosis and surgical treatment are the only options that are currently curative. Chemotherapy and radiation therapy are of limited efficacy. Methods. We reviewed the various forms of immunotherapy, concentrating on vaccine therapy. We then reviewed the history of our own vaccine in the context of the field of immunotherapy, and compared efficacy, immune response, production methods, and survival. Results. Survival is improved among recipients of melanoma vaccine when compared with patients receiving conventional therapy. Conclusions. Immunotherapy in the form of melanoma vaccines is better than conventional therapy and is trending toward purer antigenic preparations.

AB - Background. In 1998, 41,600 new cases of melanoma with 7,300 deaths were expected. Worldwide, the incidence has risen 5% a year against a backdrop of generally decreasing cancer trends. Later stages of melanoma carry a severe prognosis. The need for newer, more effective therapeutic strategies for cancer is obvious. For melanoma, early diagnosis and surgical treatment are the only options that are currently curative. Chemotherapy and radiation therapy are of limited efficacy. Methods. We reviewed the various forms of immunotherapy, concentrating on vaccine therapy. We then reviewed the history of our own vaccine in the context of the field of immunotherapy, and compared efficacy, immune response, production methods, and survival. Results. Survival is improved among recipients of melanoma vaccine when compared with patients receiving conventional therapy. Conclusions. Immunotherapy in the form of melanoma vaccines is better than conventional therapy and is trending toward purer antigenic preparations.

UR - http://www.scopus.com/inward/record.url?scp=0032766944&partnerID=8YFLogxK

U2 - 10.1097/00007611-199907000-00008

DO - 10.1097/00007611-199907000-00008

M3 - Article

C2 - 10414478

AN - SCOPUS:0032766944

VL - 92

SP - 698

EP - 704

JO - Southern Medical Journal

JF - Southern Medical Journal

SN - 0038-4348

IS - 7

ER -